{"id":"aer-001","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-13 is a cytokine involved in the pathogenesis of asthma and other allergic diseases. By targeting IL-13, AER 001 aims to reduce inflammation and improve symptoms in patients with severe asthma.","oneSentence":"AER 001 is an investigational monoclonal antibody targeting IL-13.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:20:10.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe asthma"}]},"trialDetails":[{"nctId":"NCT00801853","phase":"PHASE2","title":"A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL","status":"COMPLETED","sponsor":"Aerovance, Inc.","startDate":"2009-03","conditions":"Asthma","enrollment":424},{"nctId":"NCT00785668","phase":"PHASE1","title":"A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects","status":"COMPLETED","sponsor":"Aerovance, Inc.","startDate":"2007-11","conditions":"Asthma","enrollment":10},{"nctId":"NCT00676884","phase":"PHASE2","title":"A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema","status":"COMPLETED","sponsor":"Aerovance, Inc.","startDate":"2006-02","conditions":"Atopic Eczema","enrollment":25},{"nctId":"NCT00535028","phase":"PHASE2","title":"A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)","status":"COMPLETED","sponsor":"Aerovance, Inc.","startDate":"2005-01","conditions":"Allergic Asthma","enrollment":24},{"nctId":"NCT00535431","phase":"PHASE2","title":"Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics","status":"COMPLETED","sponsor":"Aerovance, Inc.","startDate":"2005-12","conditions":"Allergic Asthma","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AEROVANT, BAY 16-9996, Pitrakinra","AEROVANT"],"phase":"phase_2","status":"active","brandName":"AER 001","genericName":"AER 001","companyName":"Aerovance, Inc.","companyId":"aerovance-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AER 001 is an investigational monoclonal antibody targeting IL-13. Used for Severe asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}